Seymour L, Bezwoda W R, Dansey R D
Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Breast Cancer Res Treat. 1995;36(1):61-9. doi: 10.1007/BF00690186.
In an attempt to further define the clinical utility of p-glycoprotein immunostaining in breast cancer, we examined 101 specimens from patients with advanced breast cancer. There was a significant correlation between estrogen receptor status and p-glycoprotein expression but only for low levels of p-glycoprotein. Premenopausal status appeared to correlate with increased p-glycoprotein expression, but this probably reflects patient selection as premenopausal patients had higher prior exposure to anthracyclines and were more likely to have received chemotherapy as initial treatment. P-glycoprotein expression was highly significantly correlated with expression of the proliferation related antigen Ki67, suggesting that p-glycoprotein expression may well be cell cycle dependent, with overexpression occurring in rapidly cycling cells. These findings may explain reported findings of modulation of p-glycoprotein expression by agents such as anti-oestrogens. P-glycoprotein positive staining did not, however, predict chemotherapy treatment failure or survival duration.
为了进一步明确P-糖蛋白免疫染色在乳腺癌中的临床应用价值，我们检测了101例晚期乳腺癌患者的标本。雌激素受体状态与P-糖蛋白表达之间存在显著相关性，但仅针对低水平的P-糖蛋白。绝经前状态似乎与P-糖蛋白表达增加相关，但这可能反映了患者选择因素，因为绝经前患者先前接受蒽环类药物治疗的比例较高，且更有可能接受化疗作为初始治疗。P-糖蛋白表达与增殖相关抗原Ki67的表达高度显著相关，提示P-糖蛋白表达很可能依赖于细胞周期，在快速增殖的细胞中过表达。这些发现或许可以解释抗雌激素等药物对P-糖蛋白表达的调节作用。然而，P-糖蛋白阳性染色并不能预测化疗治疗失败或生存时间。
